---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-026234"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2023-06-05T23:59:59+00:00"
generated_at: "2026-06-14T07:35:15.266743+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics enters exclusive worldwide license with Celltrion for oral adalimumab biosimilar

## Summary
- Rani obtains exclusive, worldwide, royalty-free license to Celltrion IP for oral adalimumab biosimilar via Rani's delivery technology.
- Celltrion will exclusively supply adalimumab biosimilar to Rani, with limited alternative sourcing rights if supply is disrupted.
- Rani has sole manufacturing, development, and commercialization rights; Celltrion gets right of first negotiation after Phase 1 data.
- Celltrion may terminate if development milestones not met; Rani can terminate for convenience with notice.
- No financial terms disclosed; agreement covers IP ownership and mutual indemnification.

## SEC filing metadata
- accession: 0000950170-23-026234
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2023-06-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000095017023026234/0000950170-23-026234-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000095017023026234/rani-20230601.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-026234
- JSON: https://secwatch.observer/filing/0000950170-23-026234.json
- Plain text: https://secwatch.observer/filing/0000950170-23-026234.txt

## Key facts
- Material Agreements
  Rani Therapeutics Holdings, Inc. entered into License and Supply Agreement with Celltrion, Inc. valued at Exclusive worldwide royalty-free license to intellectual property for adalimumab biosimilar product; (effective 2023-06-01).
  - Action: entry
  - Agreement: license
  - Counterparty: Celltrion, Inc.
  - Value: Exclusive worldwide royalty-free license to intellectual property for adalimumab biosimilar product;
  - Effective: 2023-06-01
  source text: On June 1, 2023, Rani Therapeutics, LLC, an operating subsidiary of Rani Therapeutics Holdings, Inc. (“Rani”), and Celltrion, Inc. (“Celltrion”) entered into a License and Supply Agreement (the “License Agreement”). Under the License Agreement, Celltrion grants Rani an exclusive, worldwide, royalty-free license to certain intellectual property to make, use, sell, offer for sale, import and otherwise exploit an orally-administered therapeutic product using Rani’s oral delivery technology and Celltrion’s adalimumab biosimilar (“Product”) and to use certain information to support the manufacture, development and commercialization of Product.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1856725/000095017023026234/0000950170-23-026234-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.